<DOC>
	<DOCNO>NCT00532532</DOCNO>
	<brief_summary>A drug call AV650 ( tolperisone HCl ) give patient spasticity associate multiple sclerosis . This study three purpose : 1 . To determine whether AV650 safe patient multiple sclerosis ; 2 . To gather early evidence whether AV650 effective treating spasticity patient multiple sclerosis ; , 3 . To assess body AV650 ingest ( Germany Czech Republic sit ) .</brief_summary>
	<brief_title>Safety Preliminary Effectiveness AV650 Patients With Spasticity Associated With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Tolperisone</mesh_term>
	<criteria>Male female subject 18 70 year age ( inclusive ) Signed date informed consent Definite MS per Poser MacDonald Criteria ( either relapse remit secondary progressive course ) Expanded Disability Status Score ( EDSS ) 3.0 6.5 ( inclusive ) Screening Stable MS least 30 day screen Female child bear potential male subject whose partner child bear potential willing ensure partner use effective doublebarrier contraception study 90 day thereafter If female , neither pregnant nursing ( Confirmation subject pregnant must establish negative serum hCG pregnancy test baseline . ) Significant spasticity least two muscle group define score 2 Ashworth scale muscle group If subject antispastic treatment , dosage , frequency , route administration must stable least 30 day Screening If subject MS treatment , dosage , frequency , route administration must stable least 30 day Screening Subjects participate another research study within 90 day Screening Significant change antispasticity medication ( dosage , frequency , route administration ) within 30 day Screening Known hypersensitivity tolperisone HCl , component , lidocaine/lidocainelike product Use tolperisone HCl within 30 day screen Significant change MS treatment ( dosage , frequency , route administration ) within 30 day Screening Spasticity due neurological disorder MS Any psychiatric disorder cognitive impairment precludes fully inform consent safe participation study Subjects suffer acute relapse MS continue suffer acute relapse MS within 90 day Baseline History alcohol substance abuse within one year Screening Concurrent clinically significant immunologic , pulmonary , renal , hepatic , endocrine disease and/or unstable major disease MS Clinically significant cardiovascular disorder , ischemic heart disease , arrhythmia , poorly control hypertension , acute myocardial infarction QT prolongation great 480 msec great 450 msec accompany partial bundle branch block , ECG abnormality judgment Investigator Diastolic blood pressure &lt; 50mmHg &gt; 105mmHg ; heart rate &lt; 50 beat per minute ( bpm ) &gt; 110bpm , 3 minute sit position ; heart rate ECG &lt; 50bpm &gt; 110bpm History epilepsy ( except childhood febrile seizure ) Current malignancy history malignancy remission five year , except basal cell skin carcinoma cervical cancer ( treatment ) Female subject pregnant , nursing , plan pregnancy course study Scheduled elective surgery procedure require general anesthesia study Subject terminally ill judgment Investigator Subject inappropriate placebo medication judgment Investigator Systemic corticosteroid therapy within 28 day randomization , exception inhale medication asthma Exacerbation MS within 30 day Baseline Regular levodopa therapy within 7 day randomization Subjects take antiarrhythmic medication Donation blood study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Multiple sclerosis</keyword>
</DOC>